Array of excitement at combo's comparison with Roche drug
USA-based Array BioPharma (Nasdaq: ARRY) and privately-held French drugmaker Pierre Fabre have announced data showing that their combination almost doubles survival in BRAF-positive melanoma compared to the Roche (ROG:SIX) drug Zelboraf (vemurafenib).
The planned analysis of overall survival (OS) from the pivotal Phase III COLUMBUS trial shows that, with treatment with the combination of encorafenib 450mg daily and binimetinib 45mg twice daily, overall survival was 33.6 months, compared to 16.9 months for patients treated with Zelboraf as a monotherapy.
The combination, which is already being reviewed by the US Food and Drug Administration, was generally well-tolerated.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze